Welcome to our dedicated page for Omnicell Com news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell Com stock.
Omnicell, Inc. (NASDAQ: OMCL) is a healthcare technology company focused on intelligent medication management, and the OMCL news page on Stock Titan aggregates company-specific updates that matter to investors and healthcare observers. Omnicell describes itself as a leader in transforming the pharmacy and nursing care delivery model, with solutions that combine automation, AI-enabled intelligence, and expert services to support clinical, operational, and financial outcomes across all settings of care.
News related to Omnicell often centers on financial results, product innovation, and strategic developments. The company regularly issues earnings releases and guidance updates, discussing performance across categories such as connected devices, technical services, SaaS and Expert Services, and consumables. Press releases also cover events like conference presentations, investor Q&A sessions, and participation in industry meetings, providing context on how management communicates its strategy and outlook.
Product and technology announcements are another key theme in OMCL news. Examples include the launch of Omnicell Titan XT, an enterprise automated dispensing system powered by the OmniSphere cloud platform, and updates on OmniSphere certifications and capabilities. Omnicell also highlights initiatives such as specialty pharmacy services, URAC Health Care Management Certification, and innovation-focused events like Omnicell Illuminate and the IV TRUST Summit, which showcase developments in robotics, smart devices, software workflows, and data and analytics.
By following OMCL news, readers can monitor how Omnicell advances its vision of autonomous medication management, how it positions its solutions for health systems, retail and specialty pharmacies, and how management addresses risks and opportunities in a regulated healthcare environment. The Stock Titan news feed helps users track these announcements in one place for ongoing reference.
Omnicell (NASDAQ:OMCL) has announced a definitive agreement to acquire FDS Amplicare for $177 million. This acquisition aims to enhance Omnicell's EnlivenHealth division by integrating a suite of financial management, analytics, and population health solutions. The deal is anticipated to broaden Omnicell’s service offerings, allowing pharmacies to improve patient outcomes and expand clinical services. The acquisition, subject to regulatory approvals, is expected to close in the second half of 2021 and will be immediately accretive to Omnicell's non-GAAP earnings.
Omnicell has expanded its Board of Directors from 9 to 10 members with the appointment of Edward P. Bousa as an independent director. Mr. Bousa, a former executive at Wellington Management Company, brings nearly 40 years of asset management experience, including significant expertise in healthcare investments. His addition is part of Omnicell's strategy to refresh its board, enhancing its governance capabilities with a focus on improving health outcomes and operational efficiencies in medication management. The board now features 8 independent directors.
Omnicell, Inc. (Nasdaq: OMCL) is set to release its financial results for Q2 2021 before the market opens on July 29, 2021. A conference call to discuss these results will follow at 8:30 a.m. ET. The company's solutions aim to enhance medication management across healthcare systems, utilized by over 7,000 facilities globally. Omnicell focuses on improving patient outcomes and reducing costs through automation and analytics, benefiting over 50,000 pharmacies in North America and the UK. Investors can access the call via phone or the company’s investor relations website.
Omnicell has partnered with Chartwell Pennsylvania to implement its IVX Workflow sterile compounding technology for managing chemotherapy drug preparations. This collaboration aims to enhance safety and accuracy in medication management, utilizing gravimetric verification and barcode scanning. The system facilitates direct orders from clinical pharmacists to cleanrooms and is set for expansion to all home infusion therapies. This partnership underscores Omnicell's commitment to improving clinical outcomes and operational efficiency in pharmacy care delivery.
Omnicell, Inc. (Nasdaq: OMCL) has secured a multi-year agreement with Scripps Health to enhance pharmacy supply chain management across its San Diego network. The partnership includes the implementation of Omnicell's XT Automated Dispensing Systems and the cloud-based intelligence service, Omnicell One™. These technologies aim to improve medication management workflows, control costs, and reduce waste. Omnicell's solutions reflect a commitment to transforming the pharmacy care delivery model, positioning the company as a leader in the Autonomous Pharmacy movement.
Omnicell, a leader in medication management solutions, reported first quarter 2021 revenues of $251.8 million, a 9.6% increase year-over-year. GAAP net income was $14.1 million, or $0.30 per diluted share, up from $11.3 million in Q1 2020. Non-GAAP net income rose to $37.5 million, or $0.83 per diluted share. The company projects Q2 2021 revenues between $265 million and $270 million.
For the full year, total revenues are expected between $1.085 billion and $1.105 billion.
Omnicell, Inc. (Nasdaq: OMCL) announced a partnership between its EnlivenHealth™ division and Twilio to enhance patient engagement solutions for retail pharmacies. This collaboration aims to integrate Twilio's cloud communication technology, optimizing workflows while maintaining personal interactions. EnlivenHealth's solutions, deployed in over 30,000 pharmacies, will now include advanced features like personalized communications, SMS, and mobile apps. This partnership is part of Omnicell's vision to advance the Autonomous Pharmacy Model, improving patient outcomes and business performance for health providers.
Omnicell (Nasdaq:OMCL) has announced that Aultman Health Foundation will implement its cloud-based medication management solutions to improve safety and efficiency in central pharmacy and point-of-care settings. This partnership aims to streamline medication processes using technology such as the Central Pharmacy Dispensing Service, which combines robotic dispensing and certified technicians. The initiative aligns with Omnicell’s vision of the Autonomous Pharmacy, intended to reduce medication errors and enhance patient care quality.
Omnicell, Inc. (NASDAQ:OMCL) will announce its Q1 2021 financial results on April 29, 2021, following market close. A conference call and webcast will be held at 4:30 p.m. ET the same day to discuss the results. Interested parties can participate by calling (855) 451-1210 in the U.S. or (236) 714-3867 internationally. Over 7,000 facilities globally utilize Omnicell's solutions, significantly enhancing operational efficiency and patient safety.
Omnicell, Inc. (Nasdaq:OMCL) reports ongoing growth in its cloud-based solutions and technology-enabled services, aligning with its Autonomous Pharmacy vision. The Christ Hospital Health Network is adopting Omnicell's Central Pharmacy Dispensing Service, automating workflows and enhancing operational efficiency. This shift targets the high error rate in manual pharmacy processes and aims to free pharmacists from non-clinical duties, improving patient care. Nearly 50% of the top 300 U.S. health systems are partnering with Omnicell to achieve a zero-error medication management infrastructure.